Sanofi, GSK’s next-generation COVID-19 booster vaccine approved by the European Commission
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated